zVAD-induced autophagic cell death requires c-Src-dependent ERK and JNK activation and reactive oxygen species generation.more suppliers
In PLoS ONE, 2010
... chain 3 (LC3), Atg5, Atg7, Beclin-1, caspase 3, caspase 9, PARP, GAPDH, non-phospho- or phospho-MEK1/2 and ERK1/2 were from Cell Signaling Technology, Inc. ...
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
Cambridge, United Kingdom. In Nat Rev Cancer, 24 Oct 2015
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival.
Genistein and cancer: current status, challenges, and future directions.
Avellino, Italy. In Adv Nutr, Jul 2015
Targeting caspases, B cell lymphoma 2 (Bcl-2)-associated X protein (Bax), Bcl-2, kinesin-like protein 20A (KIF20A), extracellular signal-regulated kinase 1/2 (ERK1/2), nuclear transcription factor κB (NF-κB), mitogen-activated protein kinase (MAPK), inhibitor of NF-κB (IκB), Wingless and integration 1 β-catenin (Wnt/β-catenin), and phosphoinositide 3 kinase/Akt (PI3K/Akt) signaling pathways may act as the molecular mechanisms of the anticancer, therapeutic effects of genistein.
Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
More papers using
Beirut, Lebanon. In Int J Mol Sci, Dec 2014
Amplification of the driving oncogene KRAS(13D), which increases signaling through the ERK1/2 pathway, upregulation of the noncanonical wingless/calcium signaling pathway (Wnt), and coexisting PIK3CA mutations have all been implicated with resistance against MEK inhibitor therapy in KRAS mutated CRC.
Nuclear actin dynamics–from form to function.
In PLoS ONE, 2007
... Phospho-specific and nonphospho-specific antibodies against ERK1/2, nonmuscle myosin II, and fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse secondary and anti-FITC–HRP antibodies were obtained from Abcam. DNMT1 as a molecular target in a multimodality-resistant phenotype in tumor cells
In Molecular Cancer, 2007
... (C19), anti-Fra1(H50), anti-Nrf2 (C10), anti-Bax antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA), anti-p38, anti-p44/42, anti-cfos, anti-cjun, anti-junB, anti-junD from Active Motif, anti-Sirt1 from Biomol, anti-Stat3 ... TOR signaling in growth and metabolism
In Oncogene, 2005
... Anti-phospho Src (Ser-416 and Ser-527), anti-phospho-Akt (Ser-473), anti-phospho-S6 kinase (Thr 389), anti-phospho-RSK (Thr-573), and anti-phospho-Erk1/2 (Thr-202/Tyr-204) antibodies were purchased from Cell Signaling (Beverly, MA) ... Method of preparation of Curcurbitacin IIa as anti-cancer drugs
In British Journal of Cancer, 2005
... PARP, cleaved PARP, Histone H3, STAT3, phospho-STAT3 (tyrosine 705), JAK2, phospho-JAK2 (tyrosine 1007/1008), ERK1/2, and phospho-ERK1/2, were from Cell Signaling (Danvers, MA, USA) ... Functional analysis of PIK3CA gene mutations in human colorectal cancer.
In PLoS ONE, 2004
... anti-phospho-HER2 antibodies were purchased from Upstate Biotechnology, Anti-phospho-EGFR, anti-EGFR, anti-phospho-HER3, anti-phospho-c-Met, anti-phospho-Akt, anti-Akt, anti-PTEN, anti-phospho-ERK1/2, anti-ERK1/2, and mutation-specific (L858R in exon 21 and deletion E746-A750 in exon 19) antibodies were from Cell Signaling Technology, anti-HER3 and anti-c-Met ... Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis
In International Journal of Cell Biology, 2003
... following companies: caveolin-1 (Sigma, Mo, USA; C4490), Akt (Abcam (Cambridge, UK); ab28422), phospho-Akt (Abcam, ab27773), ERK1 (Abcam, ab9363), phospho-ERK (Santa Cruz, ... Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling
In The Journal of Experimental Medicine, 2002
... ERK1/2, phospho-ERK1/2, phospho-MEK1/2, phospho-Raf, phospho-Elk-1, phospho-p90, p38, phospho-p38, JNK, phospho-JNK, phospho-Raf and acetyl-K, phospho-MKK3/6, and MKK3 were purchased from Cell Signaling Technology ... Rhamm−/− fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair
In The Journal of Cell Biology, 1997
... muscle actin (immunohistochemistry), nonimmune IgG (Santa Cruz Biotechnology, Inc.), Ki67 (immunohistochemistry; DakoCytomation), tenascin (immunohistochemistry; Chemicon), phospho-ERK1,2 (immunohistochemistry/Western blot/immunofluorescence; Cell Signaling), CD44 (Western blot/immunofluorescence/blocking; IM7; ... Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes
In Stem Cells (Dayton, Ohio), 1990
... (3101), phospho-extracellular signal-regulated kinase (ERK)1/2 (9101), phospho-c-Jun N-terminal kinase (JNK)1/2 (9251), phospho-p38 (9211), SMAD 2 (3102), ERK1/2 (9102), and goat anti-rabbit IgG horseradish peroxidase (HRP)–linked (7074) antibodies were purchased from Cell Signaling Inc ...